Get the Stockscreener App
16.64
3.94%
0.63
Beam Therapeutics Inc stock is traded at $16.64, with a volume of 2.39M.
It is up +3.94% in the last 24 hours and down -22.75% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$16.01
Open:
$16.12
24h Volume:
2.39M
Relative Volume:
1.11
Market Cap:
$1.68B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-9.1934
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
-6.62%
1M Performance:
-22.75%
6M Performance:
-45.32%
1Y Performance:
-32.14%
1-Day Range:
$16.04
$17.12
1-Week Range:
$15.60
$18.17
52-Week Range:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
16.64 | 1.73B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
JonesTrading Reduces the PT on Beam Therapeutics (BEAM), Keeps a Buy Rating - MSN
Cantor Fitzgerald reiterates Overweight rating on Beam Therapeutics stock - Investing.com
Beam Therapeutics (BEAM) Gets a Buy from Bernstein - The Globe and Mail
Beam Therapeutics Stock Surges After FDA Grants RMAT Designation - MSN
Cathie Wood's ARK Invest ETFs Buy $46.2M in Biotech Stocks, Trim Defense Exposure - AInvest
Technical signs of recovery in Beam Therapeutics Inc.July 2025 Outlook & AI Powered Trade Plan Recommendations - Newser
Using data tools to time your Beam Therapeutics Inc. exitWeekly Trading Summary & Real-Time Volume Trigger Notifications - Newser
Measuring Beam Therapeutics Inc.’s beta against major indices2025 Price Action Summary & Smart Investment Allocation Tips - Newser
What does recent volatility data suggest for Beam Therapeutics Inc.July 2025 Short Interest & AI Enhanced Trade Execution Alerts - Newser
Is Beam Therapeutics Inc. stock bottoming outJuly 2025 Outlook & Daily Momentum Trading Reports - Newser
Beam Therapeutics: Navigating Risks and Innovation in Gene Editing - AInvest
Beam Therapeutics: A Slow-Developing Story (NASDAQ:BEAM) - Seeking Alpha
Beam Therapeutics Inc. stock prediction for this weekEarnings Performance Report & Free AI Powered Buy and Sell Recommendations - Newser
Evaluating Beam Therapeutics Inc. with trendline analysisTrade Entry Report & Fast Entry High Yield Stock Tips - Newser
Should you hold or exit Beam Therapeutics Inc. nowEarnings Performance Report & AI Powered Market Entry Strategies - Newser
Will Beam Therapeutics Inc. rebound enough to break evenMarket Performance Summary & Weekly Setup with High ROI Potential - Newser
Is Beam Therapeutics Inc. a strong candidate for buy and hold2025 Earnings Impact & Detailed Earnings Play Strategies - thegnnews.com
Understanding Beam Therapeutics Inc.’s price movement2025 Momentum Check & Free Community Consensus Stock Picks - Newser
Is Beam Therapeutics Inc. likely to announce a buybackMarket Trend Report & Short-Term High Return Strategies - sisa-n.com
Applying Wyckoff theory to Beam Therapeutics Inc. stockDollar Strength & Risk Managed Investment Strategies - Newser
Chart overlay techniques for tracking Beam Therapeutics Inc.Insider Selling & Daily Chart Pattern Signal Reports - Newser
Is Beam Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideJuly 2025 Action & Free Growth Oriented Trading Recommendations - Newser
FMR LLC Boosts Stake in Beam Therapeutics Amidst Financial Challenges - AInvest
BEAM-101 Receives RMAT for the Treatment of Sickle Cell Disease - Pharmacy Times
Beam Therapeutics announces U.S. FDA granted RMAT to BEAM-101 - TipRanks
Beam Therapeutics stock surges after FDA grants RMAT designation By Investing.com - Investing.com Canada
Beam Therapeutics stock surges after FDA grants RMAT designation - Investing.com India
Beam Therapeutics Gets FDA Regenerative Medicine Status for BEAM-101 to Treat Sickle Cell Disease - MarketScreener
Beam gains FDA Regenerative Medicine Advanced Therapy status for sickle cell treatment - Seeking Alpha
Beam Therapeutics' Sickle Cell Treatment Gets FDA's Generative Medicine Advanced Therapy Designation - MarketWatch
Beam Therapeutics up after FDA's tag for sickle cell therapy - TradingView
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | BEAM Stock News - GuruFocus
FDA grants RMAT designation to Beam Therapeutics’ sickle cell therapy By Investing.com - Investing.com Australia
FDA grants RMAT designation to Beam Therapeutics’ sickle cell therapy - Investing.com
Beam Therapeutics Announces U.S. FDA Regenerative Medicine - GlobeNewswire
Beam's Sickle Cell Gene Therapy Gets FDA Speed Boost After Strong Trial Data in 30 Patients - Stock Titan
Unlocking 100%+ Upside: Top Analysts Reveal Small-Cap Stocks to Double Your Money - AInvest
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? - Yahoo Finance
Will Beam Therapeutics Inc. benefit from government policyROI-Driven Capital Plans - thegnnews.com
Applying Elliott Wave Theory to Beam Therapeutics Inc.Momentum Entry Alerts with Risk Control - Newser
Beam Therapeutics (NASDAQ:BEAM) Price Target Cut to $21.00 by Analysts at Barclays - MarketBeat
Has Beam Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewDaily Market Momentum Summary and Strategy - Newser
Beam Therapeutics Inc. Recovery Gathers Momentum on Chart SignalsFree Access to Community - beatles.ru
Cantor Fitzgerald Issues Negative Outlook for BEAM Earnings - Defense World
Using flow based indicators on Beam Therapeutics Inc.Free Fast Exit and Entry Strategy Guide - Newser
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark - MSN
William Blair Lifts Earnings Estimates for Beam Therapeutics - Defense World
Beam Therapeutics: Analyst Maintains Buy Rating Amid Promising Trials and Solid Financials - AInvest
Beam Therapeutics: A Promising Genetic Medicine Player with Multiple Upcoming Catalysts - AInvest
Zurcher Kantonalbank Zurich Cantonalbank Raises Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - 富途牛牛
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beam Therapeutics Inc Stock (BEAM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Simon Amy | Chief Medical Officer |
Jul 03 '25 |
Sale |
20.12 |
876 |
17,625 |
64,864 |
| Simon Amy | Chief Medical Officer |
Jul 01 '25 |
Sale |
16.94 |
374 |
6,336 |
65,740 |
| Bellon Christine | Chief Legal Officer |
Apr 01 '25 |
Sale |
18.35 |
5,674 |
104,122 |
117,294 |
| Evans John M. | CEO |
Apr 01 '25 |
Sale |
18.35 |
30,663 |
562,684 |
986,249 |
| Ciaramella Giuseppe | President |
Apr 01 '25 |
Sale |
18.35 |
7,434 |
136,418 |
190,216 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Apr 01 '25 |
Sale |
18.35 |
3,015 |
55,330 |
44,512 |
| Simon Amy | Chief Medical Officer |
Apr 02 '25 |
Sale |
17.73 |
20,997 |
372,294 |
65,742 |
| Simon Amy | Chief Medical Officer |
Apr 01 '25 |
Sale |
18.35 |
9,566 |
175,542 |
86,739 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):